Global /Israel /Healthcare /Drug Manufacturers - Specialty & Generic /SCNI

Scinai Immunotherapeutics Ltd.

SCNI

• NASDAQ: SCNI • Delayed

0.7138USD 22%

As of 5 June 2026, Scinai Immunotherapeutics Ltd. has a market cap of $2.48M USD, ranking #46682 globally and #620 in Israel. It ranks #4128 in the Healthcare sector, and #306 in the Drug Manufacturers - Specialty & Generic industry.

Global Rank

46682

Country Rank

620

Sector Rank

4128

Industry Rank

306

Key Stats

Market Cap

$2.48MUSD

Enterprise Value

$2.64MUSD

Revenue (TTM)

$1.31MUSD

EBITDA (TTM)

-$6.12MUSD

Net Income (TTM)

-$8.31MUSD

PS Ratio

1.6

PB Ratio

0.8

Company Profile

Country (HQ)

Israel

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Amir Reichman open_in_new

Employees

Founded

2003

Website

scinai.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
22%	26%	18%	-31%	-53%	-0.3%	-71%	-96%	-100%

News

SCNI Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	SCNI Scinai Immunotherapeutics Ltd ADR ISIN: US09073Q3039 Shares Out.: Shares Outstanding: 3.468M¹ Shares Float: 3.39M² TV: TradingView: NASDAQ: SCNI SA: Stock Analysis: NASDAQ: SCNI YF: Yahoo Finance: SCNI GF: Google Finance: NASDAQ: SCNI NQ: NASDAQ: SCNI BA: Barron's: SCNI MS: Morningstar: XNAS: SCNI	0.7138 USD	TV: TradingView: NASDAQ: SCNI SA: Stock Analysis: NASDAQ: SCNI YF: Yahoo Finance: SCNI GF: Google Finance: NASDAQ: SCNI NQ: NASDAQ: SCNI BA: Barron's: SCNI MS: Morningstar: XNAS: SCNI

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson’s syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company has a strategic collaboration with Recipharm Israel Ltd for the development of Lifecycle CDMO Platform. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (Israel)

Name	Market Cap (USD) diff.	PE	Country
Teva Pharmaceutical Industries Ltd. TLV: TEVA	$37.93B 108.92B ILS 2M%	24.2	Israel
Seach Medical Group Ltd. TLV: SEMG	$29.52M 84.78M ILS 1K%	57.3	Israel
Together Pharma Ltd. TLV: TGTR	$16.58M 47.62M ILS 570%	22.9	Israel
Allmed Solutions Ltd. TLV: ALMD	$11.35M 32.61M ILS 359%	-	Israel
IM Cannabis Corp. CSE: IMCC	$11.32M 15.74M CAD 357%	-	Israel
Nextage Therapeutics Ltd. TLV: NXTG	$9.14M 26.25M ILS 269%	-	Israel

Industry: Drug Manufacturers - Specialty & Generic (Global)

Name	Market Cap (USD) diff.	PE	Country
Revolution Medicines, Inc. NASDAQ: RVMD	$29.56B 1M%	-	United States
Zhejiang NHU Company Ltd. SHE: 002001	$15.86B 107.34B CNY 640K%	16.0	China
Cipla Ltd. NSE: CIPLA	$11.11B 1.06T INR 449K%	23.4	India
Lupin Ltd. NSE: LUPIN	$11.0B 1.05T INR 444K%	22.7	India
Haisco Pharmaceutical Group Co., Ltd. SHE: 002653	$9.1B 61.6B CNY 367K%	80.6	China
ABIVAX Société Anonyme EPA: ABVX	$8.78B 7.57B EUR 354K%	-	France

chevron_leftBack